1Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA CancerJClin,2005,55 (2) :74-108.
2Berghmans T, Paesmans M, Meert AP, et al. Comment on "servival improvement in resectable non-small cell lung cancer with (neo) adjuvant chemotherapy., results of a meta-analysis of the literature" . Lung Cancer,2006,51(2):261 262.
3Georgoulias V, Ardavanis A, Agelidou A, et al. Docetaxel versus docetaxel plus cisplatin as front-line treatment of pa- tients with advanced non-small cell lung cancer: a randomL ized, multieenter phase trial. J Clin Oneol, 2004,22 (13) 2602-2609.
5De Marinis F, Rossi A, di Maio M,et al . Treatment of ad- vanced non small-cell lung cancer: Italian Association of Tho racic Oncology (AIOT) clinical practice guidelines. Lung Cancer,2011,73(1) 1-1O.
二级参考文献12
1Gandara DR, Vokes E, Green M, et al. Activity of docetaxel in platinum-treated non-small cell lung cancer: results of a phase Ⅱ multicentertrial [J]. J ClinOncol, 2000,18(1):131-135.
2Van Kooten M, Traine G, Cinat G, et al. Single-agent gemcitabine in pretreated patients with non-small cell lung cancer: results of an argentinean multicentre phase Ⅱ trial [J]. Br J Cancer, 1999,81(5) :846-849.
3Crino L, Mosconi AM, Scagliotti GV, et al. Gemcitabine as second-line treatment for advanced non-small cell lung cancer:a phase Ⅱ trial [J]. J Clin Oncol, 1999,17(7):2081-2085.
4Marino P, Pampallona S, Preatoni A, et al. Chemotherapy vs.supportive care in advanced non-small cell lung cancer: results of a meta-analysis of the literature [J]. Chest, 1994,106(3):861-865.
5Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough?[J]. J Clin Oncol, 1993,11 (10): 1866-1872.
6Smith IE, O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small cell lung cancer: a randomized trial of three versus six courses of mitomycin,vinblastine, and cisplatin [J]. J Clin Oncol, 2001,19 (5):1336-1343.
7Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regiments for advanced non-small cell lung cancer [J]. N Engl J Med, 2002,346(2):92-98.
8Cullen M, Billingham J, Woodraffe C, et al. Mitomycin,ifosfamide, and cisplatin in unresectable non-small cell lung cancer:effects on survival and quality of life [J]. J Clin Oncol,1999,17(10): 3188-3194.
9Klastersky J, Sculier JP, Bureau G, et al. Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small cell lung cancer [J]. J Clin Oncol, 1989,7(8):1087-1092.
10Crino L, Scagliotti G, Marangolo M, et al. Cisplatingemcitabine combination in advanced non-small cell lung cancer: a phase Ⅱ study [J]. J Clin Oncol, 1997,15(1):297-303.
6Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cispl- atin vs. observation in resected non-small-cell lung cancer [ J ]. N Engl J Med, 2005,352 ( 25 ) :2589-2597.
8A1-Saleh K, Quinton C, Ellis PM. Role of pemetrexed in ad- vanced non-small-cell lung cancer : meta-analysis of random- ized controlled trials, with histology subgroup analysis [ J ]. Curr Oncol,2012,19 ( 1 ) : e9 - el5.
9Pallis AG, Georgoulias V. Is there a standard regimen for first-line treatment of advanced/metastatic non-small-ceil lung cancer? What has meta-analyses contributed to today's standard of care [ J 1. Lung Cancer,2012,75 (3) :269 - 274.
10Yoshioka H, Okamoto I, Morita S, et al. Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with ad- vanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study [ J ]. Ann Oncol, 2013,24(5) :1 326- 1 331.
